Thursday, June 17, 2021 8:50:08 PM
Good thoughts on $billions valuation pending +efficacy results.
With a decent report on efficacy after 400, Revive moves forward with India/world market. Even if EUA is delayed on US side.
I'd peg that at $2+ billion market reach with room for growth.
With a decent report on efficacy after 400, Revive moves forward with India/world market. Even if EUA is delayed on US side.
I'd peg that at $2+ billion market reach with room for growth.
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
